92 results about "Cholestasis" patented technology

The invention belongs to but is not limited to the technical field of biomedicine, and discloses application of golden amide alcohol ester to preparation of a medicine for treating cholestasis. The in-vitro cell level verifies that the golden amide alcohol ester has relatively strong activity of activating FXR and CAR. The golden amide alcohol ester can relieve the cholestasis symptom of a cholestasis model mouse. The golden amide alcohol ester can obviously reduce the content of total bile acid and bilirubin in cells, relieve cholestasis and relieve hepatocyte damage. The golden amide alcohol ester can regulate and control the protein level of transporters and metabolic enzymes related to bile acid and bilirubin through double excitation of FXR and CAR, relieve cholestasis and achieve the purposes of benefiting gallbladder and removing jaundice.

The invention discloses Pediococcus pentosaceus G41, which is separated from rumen fluid of healthy adult dairy cows in a certain cattle farm in Changchun, has the advantages of high growth speed and strong acid production capacity, and can effectively relieve cholestatic liver injury. Experiments prove that the Pediococcus pentosaceus G41 reduces the activity of serum AST, ALT and GDH of a mouse with cholestatic liver injury, reduces the content of total bile acid in blood and liver, increases the content of total bile acid in excrement, and improves cholestatic and dirty injury caused by cholestatic.

Provided are a substance and method for improving intestinal health and homeostasis, and the nutrition and development of a subject. The substance is an odd carbon fatty acid. Specifically, provided is the use of an odd carbon fatty acid in the preparation of a preparation or drug for increasing the protein expression abundance of related tight junction proteins of a subject, reducing the content of a corticotropin-releasing hormone in the intestinal tissue of a subject, improving or enhancing the intestinal mechanical barrier of a subject, maintaining the intestinal immune homeostasis of a subject, promoting the intestinal development of a subject, maintaining the energy homeostasis in intestinal cells of a subject, improving intestinal energy metabolism, promoting the development and metabolism of muscle tissue in a subject, promoting the development and metabolism of adipose tissue in a subject, reducing allergic reactions of the body and the intestinal tract of a subject, reducing the insulin resistance in a pregnant subject, controlling the blood glucose level in a pregnant subject, preventing gestational diabetes mellitus, preventing or improving intrahepatic cholestasis in a pregnant subject, preventing or treating diseases caused by Helicobacter pylori bacteria in a subject, etc.

The invention belongs to the technical field of medicine, and provides a traditional Chinese medicine composition, a traditional Chinese medicine preparation and application thereof, and the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 20-30 parts of astragalus membranaceus, 20-30 parts of phaseolus calcaratus, 5-10 parts of radix rehmanniae, 10-20 parts of endothelium corneum gigeriae galli, 10-15 parts of hawthorn and 5-20 parts of fingered citron. The traditional Chinese medicine composition disclosed by the invention has an exact curative effect on improving the liver function, total bile acid metabolism and the like of intrahepatic cholestasis in the gestation period. Clinical, animal and cell test results show that the traditional Chinese medicine composition can effectively improve symptoms and signs of intrahepatic cholestasis in the gestation period.

The invention relates to application of mesenchymal stem cells of overexpressed Numb genes in preparation of drugs for treating chronic liver diseases. The invention also provides a mesenchymal stem cell modified by genetic engineering, and the mesenchymal stem cell modified by genetic engineering is a mesenchymal stem cell of an overexpressed Numb gene. The invention provides a novel human umbilical cord mesenchymal stem cell (hUC-MSC) for treating chronic and acute hepatic failure, hepatic fibrosis and liver cirrhosis. The hUC-MSCs overexpressing the Numb gene can inhibit liver inflammatory response and hepatic fibrosis progress in a dose-dependent manner; biliary duct reaction is inhibited in a dose-dependent manner, and cholestasis is improved; the liver cell proliferation can be promoted in a dose-dependent manner, and the content of serum albumin is increased. And the treatment effects are better than those of the same dose of hUC-MSCs. The hUC-MSCsNumb-OE can be directly used as a cell for treating chronic and acute hepatic failure, hepatic fibrosis and cirrhosis, and also can be used as a tool for screening biological or chemical medicines for treating hepatic fibrosis and cirrhosis.

A therapeutic genetic construct for addressing alpha-1 antitrypsin deficiency (AATD) and associated disorders. The genetic construct encodes: (a) a first pre-miRNA; (b) a second pre-miRNA; and (c) a transgene encoding AAT(M). The pre-miRNAs inhibit the expression of alleles encoding mutant variants of AAT, such as AAT(Z), AAT(S), AAT(I), AAT(Siiyama), and AAT(Mmalton). The construct may further comprise a liver-specific promoter. A vector, such as a gorilla adenoviral vector, comprising the genetic construct. A method of treating a disease or disorder, such as COPD, bronchiectasis, neonatal cholestasis, cirrhosis, fibrosis, and hepatocellular carcinoma, comprising administering a therapeutically effective amount of the aforementioned vector. A use of the genetic construct in the manufacture of a medicament for use in treating a disease or disorder. A composition comprising the genetic construct. A kit comprising the genetic construct.

The invention provides a preparation method of a cholestatic liver injury animal model, which comprises the following steps: on the basis that a mouse is fed with a feed containing 500IU / kg vitamin A for 8 weeks to cause deficiency of vitamin A in the mouse body, performing intragastric administration of alpha-naphthyl isothiocyanate (ANIT) at 50mg / kg for 4 weeks once a week, so as to obtain the cholestatic liver injury mouse model. The blood biochemical index ALT, the liver index, the pathological structure change of the liver tissue and the bile acid deposition of the liver tissue are more obvious. The cholestatic liver injury model prepared by the preparation method can avoid the influence of inconsistent dosage and unstable model in a conventional method, and can be applied to the research fields of molecular mechanism research of occurrence and development of cholestatic liver injury, finding of cholestatic liver injury treatment medicines and methods and the like.

Provided are biomarkers for parenteral nutrition associated cholestasis (PNAC) in subjects, especially infants receiving parenteral nutrition (PN). Using such biomarkers provide methods of diagnosing and / or assessing risk of PNAC in a subject, including screening a sample from a subject believed to be at risk for PNAC for one or more biomarkers of PNAC. The biomarkers can include one or more fecal metabolites. Such biomarkers and associated methods provide neonatal intensive care unit clinicians with an additional tool for early identification of PNAC risk. Early identification of high-risk infants would enable clinicians to confidently optimize caloric nutrition with PN for infants at low risk of developing PNAC and enable proactive mitigation with alterations to the administered PN.

The invention discloses a substituted aromatic heterocyclic compound containing a spiro skeleton as well as a preparation method and application thereof, and relates to the field of medicinal chemistry, in particular to the substituted aromatic heterocyclic compound containing the spiro skeleton or pharmaceutically acceptable salt of the substituted aromatic heterocyclic compound, a necessary composition containing the compounds and medical application of the substituted aromatic heterocyclic compound. The invention relates to an application of a monoacylglyceridase inhibitor, in particular to application of the monoacylglyceridase inhibitor as a monoacylglyceridase (MAGL) inhibitor in preparation of drugs for preventing and / or treating MAGL-related diseases. Comprise depression, schizophrenia, bi-directional disorder, dyskinesia, traumatic brain injury, neuroinflammation, Parkinson's disease, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, anxiety disorder, pain, metabolic disorder, alcoholic fatty liver disease, non-alcoholic fatty liver disease, hepatic fibrosis, cholestasis, nephropathy and other related diseases.

Described are methods for treating alpha-1 antitrypsin deficiency (AATD) in a human patient in need of treatment, using pharmaceutical compositions that include AAT RNAi agents. The pharmaceutical compositions disclosed herein that include AAT RNAi agents, when administered to a human patient in need thereof, treat liver diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, increased risk of hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, fulminant hepatic failure, and other liver-related diseases.

The invention discloses an application of an epoxidase type II inhibitor, the application is the application in preparation of drugs for treating liver injury, hepatitis, hepatic fibrosis, or liver function decline or complications thereof, and the application discovers that the existing COX-2 selective inhibitors such as celecoxib and the like and a novel efficient COX-2 selective inhibitor 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, the 2, 8-deuterated dimethyl-2-(trifluoromethyl)-2H-benzopyran-3-carboxylic acid disclosed by the invention has the effects of remarkably relieving liver injury, reducing necrosis focus and inflammatory cell infiltration of liver cells and resisting cholestatic hepatic fibrosis; in addition, hepatocyte lipid accumulation and ballooning induced by high fat diet can be reduced, and the progress of lipid hepatitis is remarkably inhibited; it is found for the first time that the traditional Chinese medicine composition can significantly reduce the concentration of serum bilirubin and play a role in relieving hyperbilirubinemia caused by liver injury or liver insufficiency; the traditional Chinese medicine composition can be used for treating neonatal jaundice, congenital bile duct atresia, cholestatic cirrhosis, acute toxic hepatic failure, bilirubin increase caused by acute attack of chronic hepatitis, chronic hepatic failure or hepatic encephalopathy and the like; therefore, the method has obvious economic benefit and clinical application value.

The present invention provides an application of a marker in the preparation of related products for predicting intrahepatic cholestasis of pregnancy. Wherein, the marker includes a clinical indicator marker and / or a gene marker, and the clinical indicator marker includes a conception method indicator and any one or more of the following clinical detection indicators: total bile acid, γ-glutamyl transpeptidase, folic acid and aspartate transaminase, and the conception method indicator is whether assisted reproduction; the gene marker includes any one or more of the following: ABCA2, ALDH4A1, ANKRA2, BLVRB, ENTR1, EZR, FCHO2, HIST1H2AE, IQCE, LARS, MMP15, PXK, RNF141, SLC7A2, TGFBR2, TMEM135 and TMEM144. The use of the above markers for detection can achieve high specificity and high sensitivity risk prediction of intrahepatic cholestasis of pregnancy.

The present application provides a compound of formula (I), or an optical isomer thereof, a pharmaceutically acceptable salt, a solvated form, or a prodrug. The compound may modulate NTCP function for the prevention and / or treatment of HBV / HDV and hepatitis virus-related diseases, bile acid-related cholestasis disorders, metabolic disorders, and / or liver diseases. Additionally, the present application relates to a pharmaceutical composition comprising such a compound and a method for modulating NTCP.

The present invention relates to the use of exosomes comprising a superrepressor-I [kappa] B (srI [kappa] B) for the treatment of liver disease. The present invention provides a pharmaceutical composition for preventing or treating a liver disease, the pharmaceutical composition comprising an exosome containing a superrepressor-I [kappa] B (srI [kappa] B) as an active ingredient, the liver disease being hepatic fibrosis, cirrhosis, fatty liver, alcoholic liver disease, cholestasis, or a combination thereof.

To provide RNAi agents for inhibiting expression of the α-1 antitrypsin (AAT) gene, compositions including the AAT RNAi agents, and methods of using the same.SOLUTION: Also there are disclosed pharmaceutical compositions including one or more AAT RNAi agents together with one or more excipients capable of delivering the RNAi agents to living cells in vivo. The delivery of the AAT RNAi agents to liver cells in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, and fulminant hepatic failure.SELECTED DRAWING: Figure 9

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation and / or fibrosis in the liver, e.g., metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), primary biliary cholangitis, primary sclerosing cholangitis, alcoholic cirrhosis, hepatitis cirrhosis, cholestasis, autoimmune hepatitis, viral hepatitis B, viral hepatitis C, hemochromatosis, Wilson's disease, or alcoholic steatohepatitis, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

The application discloses application of AML-12 exosomes in preparation of medicines for treating cholestatic liver injury, relates to the technical field of biological medicine, and discloses application of AML-12 cell-derived exosomes in preparation of medicines for preventing and treating ANIT-induced cholestatic liver injury; the treatment is manifested as reduction of alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase levels in serum. The application proves that the AML-12 cell-derived exosomes have a significant treatment effect on ANIT-induced cholestatic liver injury, successfully opens up the application of the biological preparation in a brand-new disease field, and fills the blank of the prior art; through in-vivo experiments, it is proved that AML-12 exosome treatment can significantly reduce liver cell injury markers and alkaline phosphatase, a key index of cholestasis, in serum of ANIT model mice, and improve pathological injury of liver tissue, thereby constituting a complete curative effect evidence chain from function to morphology.

The invention relates to the technical field of probiotics, and discloses a probiotic preparation for improving abnormal bile diseases of newborns. According to the probiotic preparation provided by the invention, lactobacillus fermentum CECT5716, bifidobacterium breve M-16V and bifidobacterium longum subsp. Longum BB536 in the list of strains for infants are selected as a product formula, and the probiotic preparation can be used for effectively improving abnormal bile diseases of newborns, including jaundice, hyperbilirubinemia and cholestasis, and can be used for preventing and treating the abnormal bile diseases of the newborns, such as jaundice, hyperbilirubinemia and cholestasis. The problems that in the prior art, safety is insufficient, pertinence is insufficient, and clinical requirements of complex illness conditions cannot be met are effectively solved.

The invention discloses an application of an RNAm6A modification level of PTGER4 in preparation of an ICP (inductively coupled plasma) auxiliary diagnosis kit. The RNA m6A modification level of the PTGER4 in placenta tissue and whole blood of an ICP patient is remarkably reduced, and the AUC modified by the RNA m6A of the PTGER4 in the whole blood is 0.844, so that the RNA m6A modification of the PTGER4 is a biomarker highly related to ICP attack, and a laboratory support can be provided for screening, diagnosis and treatment of ICP.

The invention provides a pharmaceutical composition for treating cholestatic liver injury, and the pharmaceutical composition contains an effective amount of Ferulic acid and Wogonin. The application creatively focuses on two key links in the cholestatic liver injury process, namely (1) bile acid excretion and (2) intestinal mucous barrier protection, a synergistic component of Ferulic acid and wogonin is provided, and the optimal ratio of Ferulic acid and wogonin is verified through an experimental system. Experiments prove that the cholestatic liver injury can be effectively improved by combined application of the Ferric acid and the Wogonin which are derived from traditional Chinese medicines; in addition, the effect of the medicine composition is obviously superior to the effect of independently using the Ferric acid or the Wogonin. Wide application prospects are realized.

The present invention provides a novel heterocyclic compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for preventing or treating an autotaxin activity-related disease containing the same as an active ingredient. The heterocyclic compound according to the present invention exhibits excellent inhibitory activity against autotaxin, and is useful for the treatment and prevention of fibrotic diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, metabolic diseases, cancer and cancer metastasis, eye diseases, cholestatic forms and other forms of chronic pruritus, and acute or chronic organ transplant rejection reactions, which are autotaxin-inhibiting related diseases.

The present disclosure relates to aromatic compounds and medical uses thereof, in particular to compounds of general formula (I): wherein R1, R2, R3, R4, R5, R6 and R7 may be selected from different substituents; n is 0, 1 or 2; and X is hydroxymethyl or a carboxylic acid or a derivative thereof, such as a carboxylate, such as a carboxylic ester, glyceride, anhydride, phospholipid, carboxamide, phospholipid, or a prodrug thereof; or pharmaceutically acceptable salts, solvates, solvates of the salts, or prodrugs thereof. The present disclosure also relates to pharmaceutical and lipid compositions comprising at least one compound according to the present disclosure, and to the use of such compounds as a medicament or for treatment, in particular for the treatment of diseases associated with metabolic and liver diseases, such as non-alcoholic fatty liver diseases and cholestasis diseases. (I)

The invention belongs to the technical field of medicine, and relates to application of eriodictyol in preparation of a medicine for preventing or treating cholestasis. According to test verification, the eriodictyol can remarkably reduce the content of total bilirubin and total bile acid in serum of a cholestasis mouse constructed by bile duct ligation, and the content of total bile acid in the cholestasis mouse is reduced; the activity of alkaline phosphatase, glutamyl transferase, hyaluronidase and laminin is inhibited, the liver index is reduced, and a new thought is provided for treating cholestasis.

The invention provides application of glycoursodeoxycholic acid in treating cholestasis type acute liver injury induced by podophyllotoxin, and relates to the field of chemical medicines. Glycine ursodeoxycholic acid as an HSPA9 micromolecule agonist can reduce synthesis of bile acid, promote excretion of the bile acid and improve the cholestasis condition by adjusting FXR / Cyp7a1 / BSEP bile acid metabolic pathway. Meanwhile, the glycoursodeoxycholic acid can improve oxidative stress injury, promote cell proliferation and reduce the cell apoptosis rate to a certain extent, so that pathological injury of the liver is improved, and a new choice is provided for treating related diseases accompanied by acute liver injury.

The invention discloses a cholestasis index-based liver cancer risk prediction model construction method, which comprises the following steps: collecting chronic HBV infected person data containing 16 parameters, carrying out desensitization, carrying out stratified random sampling to divide a data set, and carrying out two-stage screening to obtain HBsAg, ALT, ALP, GGT, PLT and AFP core features; after Min-Max Scaling processing, L1 regularization logistic regression is combined with grid search and 5-fold cross validation to construct the model, and the model constructed by the method is obviously superior to a traditional CU-HCC model and a REACH-B model, especially has higher recognition capability for early HBV-PLC, and can effectively reduce the missed diagnosis rate.

Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg / kg / day.

The present invention relates to a method of prevention, delay of progression or treatment of cholestasis and / or fibrosis associated with cholestasis.

This invention discloses a veterinary drug composition containing Bupleurum chinense extract, its preparation method, and its application, belonging to the technical field of veterinary traditional Chinese medicine preparations. The composition consists of active ingredients (only saikosaponins a and d, in a mass ratio of 0.8–1.2:1, accounting for 5%–50% of the total content) and excipients (one or more of microcrystalline cellulose, magnesium stearate, and starch). The dosage form is tablets, granules, or powder, with each unit dose containing 5–20 mg of the total mass of both. In preparation, dried Bupleurum chinense roots are pulverized and enzymatically hydrolyzed with a 1:1 complex enzyme, ultrasonically extracted with an ethanol-sodium citrate mixture, purified with AB-8 macroporous resin, and freeze-dried to obtain saikosaponin powder. This powder is then mixed with the excipients and granulated, tableted, or packaged into the corresponding dosage form. This composition shows significant efficacy against fatty liver in chickens, hepatitis in pigs, and cholestasis in ducks, exhibiting stability, high purity, and high efficiency, providing a safe new option for the treatment of liver and gallbladder diseases in livestock and poultry.

The invention discloses an application of 7 [beta]-hydroxysteroid dehydrogenase (7 [beta]-HSDH) derived from ruminococcus gnavenus (ruminococcus gnavenus) in the treatment of cholestatic diseases, and relates to a preparation method of the 7 [beta]-hydroxysteroid dehydrogenase (7 [beta]-HSDH). Specifically, Escherichia coli Nissle 1917 is taken as a starting strain, a gene which is derived from ruminococcus gnus and is used for coding 7 beta-hydroxysteroid dehydrogenase is knocked in, a gene editing engineering bacterium capable of converting chenodeoxycholic acid into ursodeoxycholic acid is successfully constructed, and the engineering bacterium can be used for treating primary sclerosing cholangitis caused by cholestasis.